Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | PGR | P06401 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28205308 | 0.85 | NPC1 (0.82) | NPC1PGRSMN1; SMN2MAPTLMNA | |
| SCHEMBL22445036 | 0.79 | NPC1 (1.00) | NPC1PGRSMN1; SMN2MAPTLMNA | |
| SCHEMBL23601227 | 0.76 | MEN1 (0.51) | NPC1PGRSMN1; SMN2LMNAEPHX2 | |
| SCHEMBL25911451 | 0.75 | EPHX2 (0.43) | NPC1PGRSMN1; SMN2MAPTLMNA | |
| SCHEMBL23206304 | 0.74 | GRIN2D (0.40) | NPC1PGRLMNAEPHX2ALDH1A1 | |
| SCHEMBL23195205 | 0.74 | GRIN2D (0.40) | NPC1PGRLMNAEPHX2ALDH1A1 | |
| SCHEMBL23194820 | 0.74 | GRIN2D (0.40) | NPC1PGRLMNAEPHX2ALDH1A1 | |
| SCHEMBL14342028 | 0.74 | CA9 (0.44) | NPC1PGRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL19098273 | 0.73 | LMNA (0.48) | NPC1PGRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL22453686 | 0.73 | NPC1 (0.67) | NPC1PGRSMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070280957-A1 | Change of the Load State of Mhc Molecules | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070280957-A1 | Change of the Load State of Mhc Molecules | HLA-DRB1, MICA, CD74 | NPC1 1497/4885PGR 3720/4885SMN1; SMN2 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.